Clinical Trial Update: Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study) [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update (REVIVE) evaluating teclistamab in combination with daratumumab for high-risk smoldering/wholedown multiple myeloma, cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Smoldering Multiple Myeloma

Drugs mentioned

• DARZALEX (daratumumab)
• TECVAYLI (TECLISTAMAB-CQYV)

Snippet

Sponsor: Carl Ola Landgren, MD, PhD | Conditions: Multiple Myeloma | Phase 2 | Status: RECRUITING